Cerba Research’s Multi Omics Approaches in Hematological Malignancies
Hematological malignancies originate from the uncontrolled growth of hematopoietic and lymphoid tissues. These biologically and clinically heterogeneous disorders account for 6.5% of all cancers around the world, for approximately 9.5% of newly diagnosed cancers every year.
Due to the high level of heterogeneity in terms of cytogenetic, genetic, epigenetic, transcriptional, post-transcriptional, and metabolic alterations of hematological diseases, integrated multi-omics analyses are needed to improve clinical outcomes.
At Cerba Research, we aim to bring a multi-modal approach to precision medicine to disease. From discovery to clinical development, we provide world-class teams and capabilities worldwide to help you in your quest of novel treatment against hematological malignancies.
Phase 2 To Determine Safety And Efficacy Of A mAB CKI Combo In Relapse Refractory Multiple Myeloma (RRMM)
Discover how we managed cell isolation and counts among other routine and speciality tests for a large Relapse Refractory Multiple Myeloma study over 11,000 samples managed.
Tests including FCM, PBMC isolation and count, FISH
Phase 1 Dose Escalation Study With A Bispecific Antibody In Relapse Refractory Multiple Myeloma (RRMM)
Discover how we manage routine and specialty test for a Phase 1 study
Phase 3 CAR-T vs SOC in Relapse Refractory Multiple Myeloma (RRMM)
Discover how effective we are in immunophenotyping for a Car-T therapy take a look at this case study
AACR 2022 poster. Using solid tumor analytical validation of T-regulatory immunohistochemistry multiplex for clinical studies
Our Histoprofile®- T-reg light panel is ready for use in your clinical trials
Our in-depth analytical validation ensures the quality of this robust protocol on solid tumor tissues. Evaluate T-cell subpopulations and their spatial distribution in the tumor microenvironment.
Analyzing Multiple Biomarkers with IHC: putting a 6-plex kit to the challenge
On November 16, 2021 Cerba Research and Akoya Biosciences held a webinar on how to analyze multiple biomarkers using Immunohistochemistry (IHC). The session was a deep dive in the Tissue Microenvironment (TME) with multiplex IF (Opal™) technology, discovering how to visualize, analyze, and quantify multiple phenotypes in situ.
As part of a long-standing collaboration with Akoya Biosciences, we agreed to test our pre-validated 6-plex panel kits, including one suitable for carcinoma immune-contexture investigations (CD8, CD68, FoxP3, PD1, PD-L1, PanCK). We were also able to put into practice Akoya’s pre-set imaging protocol on the Vectra® Polaris™ and related data analysis algorithm with inForm® software.
- Ivan Masetto, PhD, Field Application Scientist South of Europe at Akoya Biosciences
- Maroua Tliba, Image Analyst at Cerba Research
White Paper: Flow Cytometry Advantages in Immunotherapy Clinical Trials
Our white paper takes an in-depth look at the world of flow cytometry. Nithianandan Selliah, Global Head of Flow Cytometry, and Ishita Modi, Director, Scientific Customer Solutions at Cerba Research, examine its unique benefits and future potential. They highlight the latest trends in technology and set out the key points to consider when planning a flow cytometry-based clinical trial and choosing a partner lab.
CerbACT Asia – Center of Excellence in Immuno-Oncology
CerbACT Asia empowers precision medicine development and drives better patient outcomes by applying deep biomarker expertise to research & clinical development strategies, combining the strengths of Cerba Research and ACT Genomics. We are enabled by cutting edge technologies in Flow Cytometry (FCM), Immunohistochemistry (IHC), and PBMC/cell isolations, while functioning as a central laboratory in the APAC region. Working with biotech, pharma, government and nongovernmental organizations, our team is ready to turn precision medicine into action!
Download the flyer to learn more on CerbACT Asia’s capabilities.
Precision Medicine in Practice for Non-Small Cell Lung Cancer (NSCLC)
At the 16th Biomarkers UK Congress in November 2021, Rania Gaspo, PhD gave a talk on implementing precision medicine for Non-Small Cell Lung Cancer. How can you bring precision medicine into practice? What roles can Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and ctDNA play?
Webinar: Turning Precision Medicine into Action in Immuno-Oncology
The challenges in immuno-oncology (I/O) drug development require deep scientific insights, generation and analysis of complex biological data, new state-of-the art technologies and both logistical & operational support across continents. The goal of immuno-oncology drug developers is to turn precision medicine into action, bringing life-changing therapies to patients.
In this webinar originally held on October 4 our experts discuss the use of Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and Flow Cytometry (FCM) within immuno-oncology, and how they can offer the comprehensive insights required for I/O clinical trials.
- Jérôme Sallette, PhD, CSO Cerba Research
- Shu Jen Chen, PhD, CSO ACT Genomics
- Sofie Vandevyver, PhD, Head of Business Operations & Marketing Cerba Research
- George Wei, PhD, Vice President R&D ACT Genomics
- Renaud Burrer, PhD, Head of Histopathology Cerba Research
- Nithianandan Selliah, PhD, Global Head Flow Cytometry Cerba Research
Submit your information below to watch the webinar or to download the slide deck to receive our expert’s insights.